About Us - Sentinus.AI®

Our Story

The Sentinus.AI® Journey

From Global Health to Precision Medicine

Sentinus.AI was founded in 2021 with a singular vision: to transform drug discovery from a game of chance into a science of precision. Born from 20 years of expertise from UAB Medicine and Gates Foundation global health projects, our proprietary AI platform represents the culmination of work based on one of the largest membrane protein simulations funded by NIH in 2015 and the largest infectious disease screening initiatives awarded by Merck Group in 2020.

Today, Sentinus.AI operates as a "boosted virtual B cell" — capable of screening 10 billion antibody sequences and selecting optimal candidates for affinity, toxicity, and efficacy in hours, not months. We use this capacity to design antibodies, enzymes, vaccines, and other biological drugs across oncology, metabolic disease, and infectious disease.

2015

NIH Funding

Largest membrane protein simulation

2020

Merck Award

Pandemic Preparedness Recognition

2021

Founded

Sentinus.AI established

2025

Phase I

First client asset in clinical trial

Vision

A world where every patient receives the drug most likely to help them — before the first prescription is written, before the first clinical trial failure, before the first preventable death from a treatment that never had a chance.

Mission

We use proprietary AI built on 20 years of expertise to screen billions of molecular candidates in hours — designing, validating, and delivering first-in-class biological drugs and diagnostics. We operate at every stage of the value chain, making precision medicine accessible, not aspirational.

Leadership

Our Team

Dr. Lurong Pan

Founder & CEO

16+ years computational chemistry, AI, and therapeutic design. Senior Investigator at Gates Foundation. Built one of Asia's largest AI-driven infectious disease platforms. PhD Molecular Biology (UAB), MS AI (Georgia Tech). Merck Pandemic Award. 100+ publications.

David Donaldson

Chief Financial Officer

Oxford (Jurisprudence), FCA. 20+ years investment banking at Salomon Brothers, Morgan Stanley, Deutsche Bank, Piper Jaffray. Founding member, Emirates Investment Authority (UAE sovereign wealth fund). Founded 4 companies across Dubai, Abu Dhabi, Riyadh.

Dr. Rita Boukamel

Chief Commercial Officer

PhD Molecular Biology (Strasbourg), postdoc ETH Zürich. 25+ years diagnostics commercial leadership at Roche, GE Healthcare, and Accelerate Diagnostics (SVP, Head of EMEA). Built networks across 40+ countries.

Scientific Advisors

Dr. Kyle Brewer

Scientific Advisor

Co-founder ETTA Biotech. Former OpenAI (biological model tuning). PhD Molecular Biophysics, UT Southwestern. Expert in advanced drug delivery and regenerative biomaterials.

Dr. Murat Tanik

Scientific Advisor

Co-director Integrated Systems Center. Co-founder, Society for Design and Process Science. PhD Computer Science, Texas A&M.

Recognition

Awards & Publications

🏆

Merck Pandemic Preparedness Award

Recognized for breakthrough work in rapid antibody design for emerging infectious diseases.

🔬

Gates Foundation Heritage

Core technology developed through global health initiatives tackling infectious disease.

📄

Nature Scientific Reports

Peer-reviewed publication with independent validation of our AI-designed antibody results.

Read Paper →

About Sentinus.AI®